St. Johns Investment Management Company LLC Decreases Stake in Pfizer Inc. (NYSE:PFE)

St. Johns Investment Management Company LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 2.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,771 shares of the biopharmaceutical company’s stock after selling 903 shares during the period. St. Johns Investment Management Company LLC’s holdings in Pfizer were worth $861,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. GUNN & Co INVESTMENT MANAGEMENT INC. acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $2,601,000. Stanley Laman Group Ltd. boosted its position in shares of Pfizer by 411.2% in the 4th quarter. Stanley Laman Group Ltd. now owns 55,599 shares of the biopharmaceutical company’s stock valued at $1,601,000 after purchasing an additional 44,722 shares during the period. Callan Capital LLC raised its holdings in shares of Pfizer by 8.8% during the fourth quarter. Callan Capital LLC now owns 11,576 shares of the biopharmaceutical company’s stock valued at $333,000 after acquiring an additional 932 shares during the period. K.J. Harrison & Partners Inc boosted its position in shares of Pfizer by 13.4% in the fourth quarter. K.J. Harrison & Partners Inc now owns 41,801 shares of the biopharmaceutical company’s stock worth $1,203,000 after buying an additional 4,952 shares during the period. Finally, Spinnaker Trust lifted its position in Pfizer by 78.3% in the 4th quarter. Spinnaker Trust now owns 86,160 shares of the biopharmaceutical company’s stock worth $2,481,000 after buying an additional 37,829 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, August 19th. BMO Capital Markets restated an “outperform” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Morgan Stanley raised their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Barclays upped their target price on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, Wells Fargo & Company raised their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Price Performance

NYSE PFE traded up $0.03 during trading hours on Monday, reaching $28.93. 16,501,232 shares of the stock traded hands, compared to its average volume of 38,871,719. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The company has a market cap of $163.93 billion, a price-to-earnings ratio of -482.17, a price-to-earnings-growth ratio of 0.98 and a beta of 0.69. The stock has a 50 day simple moving average of $28.89 and a two-hundred day simple moving average of $27.98. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $36.94.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. The business had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.67 earnings per share. On average, analysts predict that Pfizer Inc. will post 2.68 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 5.81%. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.